Advanced search×
×

Expert Opinion on Investigational Drugs

Print ISSN
1354-3784
Electronic ISSN
1744-7658
Impact factor
4.337
Publisher
Proquest
URL
http://informahealthcare.com/journal/eid
Usage rank
1216
Article count
2343
Free count
1
Free percentage
0.000426803
PDFs via platforms
CSA, Proquest, Ingenta, Informaworld, Rcgp, and Informahealthcare

  1. Na+ H+ exchanger-1: a link with atherogenesis?

    Expert Opinion on Investigational Drugs 19(12):1545 (2010) PMID 21047280

    We herein review the contribution of NHE-1 in atherogenesis (namely its effect on endothelial cells, monocytes, smooth muscle cells and platelets). What the reader will gain: Studies have shown that NHE is involved in atherogenesis-related properties of isolated monocytes. We also consider the relat...
  2. New small molecules for the treatment of Parkinson's disease.

    Expert Opinion on Investigational Drugs 19(9):1077 (2010) PMID 20645881

    We will describe how development programs of novel molecules now additionally consider non-motor features of PD as promising targets in order to obtain regulatory approval. Regulatory authorities increasingly exert influence on trial designs, demanding therapeutic effects that are not always clinica...
  3. Evolution of endocrine adjuvant therapy for early breast cancer.

    Expert Opinion on Investigational Drugs 19 Suppl 1(s1):S19 (2010) PMID 20374026

    We need the results from ongoing studies to decide what may be the optimal duration of therapy and regimen (sequential treatment versus monotherapy; one drug compared with another). Further, there is a need to critically assess optimal use of endocrine therapy for metastatic disease among patients p...
  4. Evolving pathway-driven biomarkers in breast cancer.

    Expert Opinion on Investigational Drugs 19 Suppl 1(s1):S51 (2010) PMID 20374031

    We briefly review the following pathways from the perspective of biomarkers through works from Dr Kumar's lab: i) estrogen receptor alpha (ER) signaling; ii) nuclear receptor coregulators in ER-directed therapies; iii) p21-activated kinase-1 in ER action; iv) cytoskeleton components in breast cancer...
  5. Sustained-release naltrexone: novel treatment for opioid dependence.

    Expert Opinion on Investigational Drugs 16(8):1285 (2007) PMID 17685876

    The devastating costs of opioid abuse and dependence underscore the need for effective treatments for these disorders. At present, several different maintenance medications exist for treating opioid dependence, including methadone, buprenorphine and naltrexone. Of these, naltrexone is the only one t...
  6. Recent advances in the development of telomerase inhibitors for the treatment of cancer.

    Expert Opinion on Investigational Drugs 8(12):1981 (1999) PMID 11139836

    We review recent advances in the development of telomerase inhibitors for the treatment of cancer. To date, these have included antisense strategies, reverse transcriptase inhibitors and compounds capable of interacting with high-order telomeric DNA tetraplex ('G-quadruplex') structures to prevent e...
  7. DNA vaccines for cancer therapy.

    Expert Opinion on Investigational Drugs 8(12):2017 (1999) PMID 11139838

    Vaccination with a tumour antigen-expressing plasmid DNA (pDNA) is a novel approach to human cancer immunotherapy. Initial results in preclinical rodent tumour models are promising, revealing that pDNA cancer vaccines can elicit both humoral, as well as cell-mediated immunity and, in...
  8. Endothelin receptor antagonists: novel agents for the treatment of hypertension?

    Expert Opinion on Investigational Drugs 8(11):1807 (1999) PMID 11139826

    We now possess direct evidence that such drugs are effective as antihypertensives in some experimental models of hypertension. Furthermore, the ability of ET-receptor antagonists to prevent hypertension-induced end-organ damage is also well documented. Their capacity to reverse already established t...
  9. Rosiglitazone: a new therapy for Type 2 diabetes.

    Expert Opinion on Investigational Drugs 8(10):1709 (1999) PMID 11139821

    Rosiglitazone (Avandiatrade mark) is a new generation thiazolidinedione used in the treatment of Type 2 diabetes. As with other thiazolidinediones, it binds to the gamma-isoform of the peroxisome proliferator-activated receptor (PPAR), a nuclear hormone receptor. Subsequent to PPAR-g...
  10. Recent advances in transgenic model development for Alzheimer's disease.

    Expert Opinion on Investigational Drugs 7(12):2017 (1998) PMID 15991944

    The lack of a small animal model that represents major features of Alzheimer's disease has long been considered a major handicap for research and drug development. Transgenic technology has been used to introduce potential pathological start points as well as established genetic causes of the diseas...